Abstract
Mantle cell lymphoma (MCL) is an uncommon B-cell lymphoma that prototypically expresses CD5, but a small subset is CD5 negative. The clinical significance of CD5 negativity is not yet well-elucidated. This case series aims to contribute to the understanding of CD5-negative MCL by looking at specific markers and outcome in our cases with long-term follow-up. Eight cases of CD5-negative MCL were identified in the case files at the Massachusetts General Hospital from 1978 to 2016. Clinicopathological characteristics were evaluated, including immunohistochemical stains for cyclin D1, SOX11, Ki67, and p53. Patients initially presented with involvement of lymph nodes and spleen (n = 4), sinonasal or oral mucosa (n = 2), orbital soft tissue (n = 1), and salivary gland (n = 1). On histology, the cases all showed classic MCL morphology, with a monotonous population of medium-sized cells with irregular nuclear contours. The cases were positive by immunohistochemistry for cyclinD1 (8/8 cases), essentially negative for p53 staining (8/8 cases), and mostly positive for SOX11 (5/8 cases). All cases had a low Ki67 proliferation rate (<5%). Long-term clinical follow-up on five cases showed that four patients had a clinical course complicated by multiple relapses to the skin, soft tissue, liver, and bone marrow. Seven cases with available follow-up showed an average survival of 121 months (SD 86 months), with no detectable survival difference between the SOX11 positive and negative cases. CD5-negative MCL is an uncommon subtype of MCL that overall appears to have a better prognosis and longer overall survival than classic MCL, despite SOX11 expression. The cases also show little p53 expression and a low Ki67 proliferation index.
Similar content being viewed by others
References
Swerdlow SH (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390. doi:10.1182/blood-2016-01-643569
Avet-Loiseau H, Garand R, Gaillard F, Daviet A, Mellerin MP, Robillard N, Bouyge I, Arcot S, Batzer M, Talmant P, Harousseau JL, Milpied N, Bataille R (1998) Detection of t(11;14) using interphase molecular cytogenetics in mantle cell lymphoma and atypical chronic lymphocytic leukemia. Genes Chromosomes Cancer 23(2):175–182. doi:10.1002/(SICI)1098-2264(199810)23:2%3C175::AID-GCC11%3E3.0.CO;2-N
Li JY, Gaillard F, Moreau A, Harousseau JL, Laboisse C, Milpied N, Bataille R, Avet-Loiseau H (1999) Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am J Pathol 154(5):1449–1452. doi:10.1016/S0002-9440(10)65399-0
Abrahamsson A, Albertsson-Lindblad A, Brown PN, Baumgartner-Wennerholm S, Pedersen LM, D’Amore F, Nilsson-Ehle H, Jensen P, Pedersen M, Geisler CH, Jerkeman M (2014) Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. Blood 124(8):1288–1295. doi:10.1182/blood-2014-03-559930
Carvajal-Cuenca A, Sua LF, Silva NM, Pittaluga S, Royo C, Song JY, Sargent RL, Espinet B, Climent F, Jacobs SA, Delabie J, Naresh KN, Bagg A, Brousset P, Warnke RA, Serrano S, Harris NL, Swerdlow SH, Jaffe ES, Campo E (2012) In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica 97(2):270–278. doi:10.3324/haematol.2011.052621
Hsi ED, Martin P (2014) Indolent mantle cell lymphoma. Leuk Lymphoma 55(4):761–767. doi:10.3109/10428194.2013.815353
Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, Diliberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP (2009) Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 27(8):1209–1213. doi:10.1200/JCO.2008.19.6121
Ondrejka SL, Lai R, Smith SD, Hsi ED (2011) Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 96(8):1121–1127. doi:10.3324/haematol.2010.036277
Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E, Catovsky D, Thomas PW, Avet-Loiseau H, Oscier D (2003) A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 101(12):4975–4981. doi:10.1182/blood-2002-06-1864
Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wormann B, Ludwig WD, Duhrsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111(2):558–565. doi:10.1182/blood-2007-06-095331
Hoster E, Klapper W, Hermine O, Kluin-Nelemans HC, Walewski J, van Hoof A, Trneny M, Geisler CH, Di Raimondo F, Szymczyk M, Stilgenbauer S, Thieblemont C, Hallek M, Forstpointner R, Pott C, Ribrag V, Doorduijn J, Hiddemann W, Dreyling MH, Unterhalt M (2014) Confirmation of the mantle-cell lymphoma international prognostic index in randomized trials of the European mantle-cell lymphoma Network. J Clin Oncol 32(13):1338–1346. doi:10.1200/JCO.2013.52.2466
Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C, Barth TF, Brousse N, Pileri S, Rymkiewicz G, Kodet R, Stilgenbauer S, Forstpointner R, Thieblemont C, Hallek M, Coiffier B, Vehling-Kaiser U, Bouabdallah R, Kanz L, Pfreundschuh M, Schmidt C, Ribrag V, Hiddemann W, Unterhalt M, Kluin-Nelemans JC, Hermine O, Dreyling MH, Klapper W (2016) Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma Network. J Clin Oncol 34(12):1386–1394. doi:10.1200/JCO.2015.63.8387
Halldorsdottir AM, Lundin A, Murray F, Mansouri L, Knuutila S, Sundstrom C, Laurell A, Ehrencrona H, Sander B, Rosenquist R (2011) Impact of TP53 mutation and 17p deletion in mantle cell lymphoma. Leukemia 25(12):1904–1908. doi:10.1038/leu.2011.162
Nygren L, Baumgartner Wennerholm S, Klimkowska M, Christensson B, Kimby E, Sander B (2012) Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood 119(18):4215–4223. doi:10.1182/blood-2011-12-400580
Slotta-Huspenina J, Koch I, de Leval L, Keller G, Klier M, Bink K, Kremer M, Raffeld M, Fend F, Quintanilla-Martinez L (2012) The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index. Haematologica 97(9):1422–1430. doi:10.3324/haematol.2011.055715
Tiemann M, Schrader C, Klapper W, Dreyling MH, Campo E, Norton A, Berger F, Kluin P, Ott G, Pileri S, Pedrinis E, Feller AC, Merz H, Janssen D, Hansmann ML, Krieken H, Moller P, Stein H, Unterhalt M, Hiddemann W, Parwaresch R (2005) Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 131(1):29–38. doi:10.1111/j.1365-2141.2005.05716.x
Shapiro JL, Miller ML, Pohlman B, Mascha E, Fishleder AJ (1999) CD5- B-cell lymphoproliferative disorders presenting in blood and bone marrow. A clinicopathologic study of 40 patients. Am J Clin Pathol 111(4):477–487
Zapata M, Budnick SD, Bordoni R, Li S (2010) An uncommon case of de novo CD10+ CD5- mantle cell lymphoma mimics follicle center B cell lymphoma. Int J Clin Exp Pathol 3(4):430–436
Yoo SB, Kim YA, Jeon YK, Kim CW (2008) CD5-undetected by immunohistochemistry, t(11;14)(q13;q32)-positive conjunctival mantle cell lymphoma: a case report. Pathol res Pract 204(10):779–783. doi:10.1016/j.prp.2008.04.009
Liu Z, Dong HY, Gorczyca W, Tsang P, Cohen P, Stephenson CF, Berger CS, Wu CD, Weisberger J (2002) CD5- mantle cell lymphoma. Am J Clin Pathol 118(2):216–224. doi:10.1309/TE56-A43X-29TT-5H8G
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shih, A.R., Bledsoe, J.R., McKelvie, P. et al. CD5-negative mantle cell lymphoma shows a less aggressive outcome and variable SOX11 staining. J Hematopathol 10, 49–53 (2017). https://doi.org/10.1007/s12308-017-0292-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12308-017-0292-0